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 The transforming growth factor beta induced protein
(TGFBIp; also known as kerato-epithelin, beta ig-h3, βig-h3,
RGD-containing collagen-associated protein [RGD-CAP], and
MP78/70) is an extracellular matrix protein encoded by the
transforming growth factor beta induced gene (TGFBI; for-
merly designated BIGH3), which was first discovered in a lung
adenocarcinoma cell line exposed to transforming growth fac-
tor beta [1]. The protein is composed of 683 residues includ-
ing a 23-amino acid signal peptide. TGFBIp is highly con-
served and the full-length human and porcine TGFBIp se-
quences are 93% identical [2]. TGFBIp contains an RGD motif
(residues Arg619-Gly620-Asp621 in mature TGFBIp) and has been
shown to interact with different integrins [3-7], fibronectin
[8], collagen types I, II, IV, and VI [9,10] and to stimulate cell
migration. Thus, the interaction of TGFBIp with these ligands
suggests that TGFBIp plays a role in cell adhesion but its spe-
cific physiological role remains unclear.
The TGFBI gene is expressed in many tissues but TGFBIp
is especially abundant in the cornea [11,12], skin [13], bone
[14], cartilage [9], tendon [15], and kidney [16]. We discov-
ered TGFBIp in the normal human cornea [12] and have re-
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Purpose: Several inherited corneal disorders in humans result from mutations in the transforming growth factor beta
induced gene (TGFBI), which encodes for the extracellular transforming growth factor beta induced protein (TGFBIp)
that is one of the most abundant proteins in the cornea. We previously reported a significant amount of TGFBIp in plasma
by immunoblotting using the only TGFBIp antiserum (anti-p68βig-h3) available at that time (anti-p68βig-h3 was generated
against residues Val210-His683 of TGFBIp). This observation raised the possibility that a fraction of corneal TGFBIp may
originate from the plasma. However, recent experiments in our laboratory indicated that the anti-p68βig-h3 antiserum cross-
reacts with an environmental protein contaminant. Therefore, we investigated the specificity of the originally utilized anti-
p68βig-h3 antiserum and re-evaluated the amount of TGFBIp in human plasma by immunoblotting using a new specific
antiserum.
Methods: The observed cross-reactivity of the previously utilized anti-p68βig-h3 antiserum was tested by immunoblotting
and the antigen identity was determined by mass spectrometry. A part of human TGFBI encoding an NH2-terminal 11.4
kDa fragment of TGFBIp (residues Gly134-Ile236) was amplified by polymerase chain reaction (PCR) and cloned in E. coli.
The TGFBIp fragment was expressed in E. coli, purified by Ni2+-affinity chromatography, and used to immunize rabbits to
produce a specific antiserum (anti-TGFBIp134-236). To enhance the detection of possible TGFBIp in plasma by allowing a
higher sample load, albumin and immunoglobulin G (IgG) were specifically depleted from normal human plasma by
affinity chromatography. The presence of TGFBIp in plasma was investigated by immunoblotting using the anti-TGFBIp134-
236 antiserum. Purified TGFBIp from porcine corneas was used for estimation of the TGFBIp detection limit.
Results: The previously utilized TGFBIp antiserum, anti-p68βig-h3, cross-reacted with human keratin-1, a common envi-
ronmental protein contaminant. Thus, the anti-p68βig-h3 antiserum recognizes both TGFBIp and keratin-1. In contrast, the
anti-TGFBIp134-236 antiserum reacted with TGFBIp but showed no indication of reactivity with other proteins in plasma.
Using this antiserum, TGFBIp was not detected in crude or albumin/IgG-depleted human plasma and the detection limit
of TGFBIp using immunoblotting was estimated to be 10 ng.
Conclusions: Our failure to detect TGFBIp in human plasma using a highly specific antiserum suggests that TGFBIp is
not present in a physiologically relevant concentration in human plasma. The previous impression that normal human
plasma contains a significant amount of TGFBIp by immunoblotting was due to the utilization of a less specific antiserum
that recognizes both TGFBIp and human keratin-1. Together with other results, our observation makes it unlikely that
TGFBIp is imported into the cornea from the circulation as reported for other abundant extracellular corneal proteins and
suggests corneal origin of TGFBIp deposits in individuals with inherited corneal diseases caused by mutations in the
TGFBI gene.
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997cently purified and characterized the protein from human and
porcine corneas [2]. Most of the corneal TGFBIp has a ma-
ture molecular mass of 68 kDa and migrates as an about 65
kDa protein in reducing sodium dodecyl sulfate-polyacryla-
mide gel electrophoresis (SDS-PAGE). The corneal TGFBIp
is truncated in the COOH-terminus immediately after the pu-
tative integrin-binding sequence (RDG) and most likely lacks
posttranslational modifications. In addition, about 60% of the
corneal TGFBIp is covalently associated with insoluble com-
ponents.
Mutations in the TGFBI gene are associated with an ac-
cumulation of TGFBIp in several inherited corneal disorders
that lead to impaired vision [17-19]. Some mutations result in
an accumulation of amyloid within the corneal stroma
[18,20,21] while others generate fuschinophilic crystalloid
deposits in the cornea that are characteristics of the granular
corneal dystrophies. Furthermore, the Arg124His mutation
gives rise to a combination of granular and amyloid deposits
while mutation Arg555Gln causes curly fibers characteristic
of Thiel-Behnke dystrophy [18]. In a recent systemic investi-
gation of TGFBIp deposits in a patient with lattice corneal
dystrophy type I, deposits were not detected in any tissue ex-
cept the cornea, suggesting a cornea-specific mechanism for
the TGFBIp accumulations [22].
The TGFBI gene is highly expressed in the corneal epi-
thelium [11] and stromal cells [23], suggesting that wild-type
and mutant TGFBIp are synthesized locally in normal and dis-
eased corneas. However, significant amounts of TGFBIp have
been reported in plasma from a healthy person and an indi-
vidual with granular corneal dystrophy [24] using the only
antiserum against TGFBIp available at the time (anti-p68βig-
h3) [25]. This suggested that at least some corneal TGFBIp
may originate from plasma. That some corneal proteins are
derived from the plasma is well established. Thus,
bioinformatic comparison of the cornea proteome [26] with
high quality gene expression data from the cornea strongly
indicates that most plasma proteins are not synthesized in the
cornea [27] but probably enter this tissue from neighboring
blood vessels. The possibility that TGFBIp deposition in the
TGFBI corneal disorders might be plasma derived was sup-
ported by the somewhat comparable human disease
hypergammaglobulinemia. Immunoglobulin normally enters
the cornea from plasma and in hypergammaglobulinemia, this
protein sometimes aggregates and deposits in the cornea [28-
32].
However, recently we have noticed that the anti-p68βig-h3
utilized to immunodetect TGFBIp in plasma reacted with an-
other protein, raising doubt on the conclusion that human
plasma contains significant amounts of TGFBIp [24]. We hence
examined the specificity of the previously utilized antiserum,
anti-p68βig-h3. Here, we report that it is not only specific against
TGFBIp but also reacts with human keratin-1, a common en-
vironmental protein contaminant having approximately the
same molecular mass as TGFBIp. Using a new and highly
specific antiserum (anti-TGFBIp134-236) for immunodetection
of TGFBIp, we conclude that the previous strong detection of
TGFBIp in normal human plasma was in error and that TGFBIp
is not detectable in normal human plasma under the condi-
tions tested. Thus, our results suggest that corneal TGFBIp is
not imported into the cornea from plasma but originates from
local synthesis in the cornea.
METHODS
Cloning and purification of the NH2-terminal transforming
growth factor beta induced protein fragment:  A human NH2-
terminal 11.4 kDa TGFBIp-fragment covering residues Gly134-
Ile236 of the full-length precursor protein (Gly111-Ile213 of the
mature protein) was cloned by PCR using forward primer 5'-
CAC CGG GCC CGG CAG CTT CAC CAT CTT CG-3', re-
verse primer 5'-TCA GAT GAC CTT ATC GAT CGA TGA
GGT G-3', and human full-length TGFBI cDNA as template.
The resulting PCR product was inserted into the expression
plasmid pET100/D-TOPO (Invitrogen, Taastrup, Denmark)
thereby introducing an NH2-terminal His6-tag. E. coli strain
TOP10F’ (Invitrogen, Taastrup, Denmark) was transformed
with the plasmid and the transformed cells were selected on
Luria Broth (LB) medium/agar plates. The sequence of the
insert was verified by DNA sequencing.
E. coli strain BL21 Star™ (DE3) from Invitrogen
(Taastrup, Denmark) was transformed with the plasmid and
cultured in LB medium at 37 °C. Protein expression was in-
duced by adding isopropyl-beta-D-thiogalactopyranoside
(IPTG) to a final concentration of 1 mM and the cells were
grown for two h. Cells were harvested by centrifugation, sus-
pended in 40 ml Tris-buffered saline (TBS; 20 mM Tris-HCl,
pH 7.6, and 137 mM NaCl) and lysed three times in a French
press. The crude cell extract was centrifuged at 22,000x g for
30 min at 4 °C and the insoluble fraction was dissolved at 4
°C in 8 ml 20 mM Tris-HCl (pH 7.4), 10 mM imidazole, and
6 M guanidine, before being centrifuged at 16,000x g for 20
min. The resulting supernatant was filtered and loaded onto a
HiTrap Ni2+-affinity column (Amersham Biosciences, Little
Chalfont, England) and the column was washed thoroughly
with 20 mM Tris-HCl (pH 7.4), 500 mM NaCl, 10 mM imida-
zole, and 6 M guanidine. The His-tagged NH2-terminal frag-
ment of TGFBIp was eluted stepwise with 20, 40, 60, and 100
mM imidazole in the same buffer. Each fraction was dialyzed
into 20 mM ammonium bicarbonate and precipitated proteins
were analyzed by reduced SDS-PAGE. The 60 mM and 100
mM eluates were dried in a speed vac and resuspended in 50
mM Hepes (pH 7.4) and 100 mM NaCl.
Production of antiserum (anti-TGFBIp134-236) and deter-
mination of detection limit:  Rabbits were immunized five times
subcutaneously with approximately 60 µg of the NH2-termi-
nal TGFBIp-fragment per injection at four-week intervals. To
determine the detection limit of the anti-TGFBIp134-236 antise-
rum, immunoblotting was performed with increasing amounts
(2 ng-0.5 µg) of porcine corneal TGFBIp that had been puri-
fied as previously described [2].
Depletion of albumin and IgG from human plasma:  Nor-
mal human plasma obtained from the Danish National Serum
Institute, Copenhagen was depleted of albumin and IgG by
affinity chromatograpy. First, albumin was depleted using
agarose immobilized Anti-HSA Affibody molecule (Affibody
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998AB, Bromma, Sweden) [33,34] following the manufacturer’s
recommended protocol. Secondly, the flow-through was di-
luted five times in 20 mM NaH2PO4 (pH 7.0) and applied to a
Protein G Sepharose™ 4 Fast Flow resin (Amersham Bio-
sciences, Little Chalfont, England) equilibrated in the same
buffer. The flow-through was dialyzed into 10 mM ammo-
nium bicarbonate, lyophilized in a speed vac, and dissolved in
20 mM Tris-HCl (pH 7.4) and 100 mM NaCl to a final vol-
ume equaling that of the crude plasma. The column materials
used for the removal of albumin and IgG did not have affinity
for TGFBIp (data not shown).
SDS-polyacrylamide gel electrophoresis (SDS-PAGE):
Blank samples containing SDS sample buffer and increasing
amounts of dithiothreitol (DTT; 0-50 mM) were prepared and
boiled to investigate the cross-reactivity of the anti-p68βig-h3
antiserum directed against TGFBIp-fragment Val210-His683 of
the precursor protein. The anti-p68βig-h3 antiserum was the first
antiserum generated against TGFBIp [25]. The plasma samples
and purified corneal TGFBIp were boiled in SDS sample buffer
containing 10 mM DTT. All samples were analyzed on 5-15%
linear gradient gels (10x10x0.1 cm) using the 2-amino-2-me-
thyl-1,3 propandiol (ammediol)/glycine/HCl buffer system as
described by Bury [35].
Immunoblotting:  Following SDS-PAGE, proteins were
electroblotted to a polyvinylidene difluoride (PVDF) mem-
brane (Millipore Immobilon transfer membranes, Millipore,
Bedford, MA) and analyzed by immunoblotting. The PVDF
membranes were blocked in 30 ml 1% dry milk solution in
Tris-buffered saline with 0.1% Tween (TBS-T; 20 mM Tris-
HCl, pH 7.6, 137 mM NaCl, and 0.1% Tween) for one h at
room temperature before the rabbit antiserum against human
TGFBIp was added to the blocking solution. The previous
utilized anti-p68βig-h3 antiserum [24] was diluted 1:20,000,
while the anti-TGFBIp134-236 antiserum against the NH2-termi-
nal fragment of TGFBIp was diluted 1:2,000. After an over-
night incubation with the primary antibody at 4 °C, the mem-
brane was washed 3x15 min with TBS-T and then incubated
for two h at room temperature in 60 ml of TBS-T containing 2
µl of anti-rabbit IgG peroxidase conjugate (Sigma Chemical
Co., St. Louis, MO) and washed 3x15 min with TBS-T. Fi-
nally, the membranes were developed for one min using the
enhanced chemiluminescence western blotting detection sys-
tem and reagents (Amersham Biosciences, Little Chalfont,
England). Purified TGFBIp from porcine corneas was used as
a control.
Collection and analysis of dust:  Normal environmental
dust collected from three locations in the laboratory was
pooled, and suspended in sample buffer containing 35 mM
DTT to a final and absolute concentration of 50 mg/ml. The
suspension was boiled for five min and centrifuged, then the
supernatant (stock) was analyzed by SDS-PAGE.
Protein visualization and identification by matrix-assisted
laser desorption ionization mass spectrometry:  Proteins sepa-
rated by SDS-PAGE were visualized by silver or coomassie
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Figure 1. The anti-p68βig-h3 antiserum shows strong reactivity with a
protein-contaminant under reducing conditions.  The immunoblot
shows sample buffer as blank samples containing increasing amounts
of DTT. The anti-p68βig-h3 antiserum against residues Val210-His683 of
the TGFBIp precursor was used in a dilution ratio of 1:20,000. Lanes
1-7 contain sample buffer with increasing amounts of DTT (0-50
mM). Lane 8 shows 0.16 µg of TGFBIp in sample buffer containing
35 mM DTT. Lane 9 shows 0.16 µg of TGFBIp in sample buffer in
the absence of DTT. Lane 10 is the molecular weight standard.
Figure 2. Analysis and identification of the environmental protein
contaminants.  Silver stained SDS gel of blank and dust samples.
Lanes 1-3 show blank samples containing sample buffer and 35 mM
DTT. Lane 4 shows proteins extracted from 25 µg of normal envi-
ronmental dust in sample buffer containing 35 mM DTT. The upper
band (about 65 kDa) is keratin-1 and the lower band (60 kDa) is
keratin-10.
999brilliant blue staining as indicated. The protein bands of inter-
est were excised and prepared for matrix-assisted laser des-
orption ionization mass spectrometry (MALDI) analysis as
previously described for 2-D gel spots [36]. MALDI-time of
flight mass spectrometry (MALDI-TOF MS) data was acquired
using a Quadrupole-time of flight (Q-TOF) Ultima Global
instrument (Micromass/Waters Corp., Manchester, United
Kingdom) and the peak list of peptides were used to query all
entries of the Swiss-Prot protein database on a local Mascot
server using the Mascot search engine (Matrix Sciences, Lon-
don, United Kingdom). The searches were performed with a
peptide mass tolerance of 50 parts per million (ppm).
Propionamide was selected as fixed modification of cysteine
residues, and oxidation of methionine residues was selected
as variable modification in the searches. In addition, a single
missed tryptic cleavage was allowed. Only significant hits as
defined by Mascot probability analysis were accepted.
RESULTS
 Recent observations in our laboratory have indicated that the
anti-p68βig-h3 antiserum generated against residues Val210-His683
of the precursor TGFBIp strongly reacts against another pro-
tein. Therefore, the specificity of this antiserum was analyzed
by immunoblotting using sample buffer as blank samples with
increasing concentrations of DTT (Figure 1, lanes 1-7). Using
non-reducing conditions, the antiserum did not react with the
blank sample (Figure 1, lane 1). However, the antiserum re-
acted strongly with a protein of about 65 kDa as the concen-
tration of DTT was increased (Figure 1, lanes 2-7). In addi-
tion, the reactivity of the anti-p68βig-h3 antiserum against
samples containing TGFBIp was tested under both reducing
and non-reducing conditions (Figure 1, lanes 8 and 9). As ex-
pected, the antiserum showed strong reactivity against a pro-
tein contaminant (about 65 kDa) in the presence of 35 mM
DTT (Figure 1, lane 8). Under non-reducing conditions (Fig-
ure 1, lane 9) only TGFBIp (about 64 kDa) is recognized by
the anti-p68βig-h3 antiserum. Thus, this antiserum reacted
strongly with a protein contaminant following reduction of
disulfides, which also explains the apparent reaction with the
molecular weight marker (Figure 1, lane 10).
To determine the identity and origin of the approximately
65 kDa contaminating protein recognized by the antiserum,
blank samples (Figure 2, lanes 1-3) and normal environmen-
tal dust that was dissolved in sample buffer containing 35 mM
DTT (Figure 2, lane 4) were separated by SDS-PAGE and the
proteins were visualized by silver staining. Both the blank and
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Figure 3. Purification of recombinant NH2-terminal TGFBIp frag-
ment.  The His-tagged NH2-terminal TGFBIp-fragment (residues
Gly134-Ile236) was expressed in E. coli and purified from the insoluble
fraction using Ni2+-affinity chromatography. The step-wise elution
was analyzed by SDS-PAGE and the gel was stained with coomassie
brilliant blue. Lane 1 shows the eluate from elution buffer containing
40 mM imidazole. Lane 2 contains the eluate from 60 mM imida-
zole. Lane 3 contains the eluate from 100 mM imidazole. All lanes
contain 50 µl of the elution.
Figure 4. Immunoblotting of crude human plasma using the specific
anti-TGFBIp134-236 antiserum.  The immunoblot shows increasing
amounts of crude human plasma diluted in 20 mM Tris-HCl (pH 7.4)
and 100 mM NaCl. Each lane contains 20 µl of diluted crude plasma.
Lane 1 contains 0.2 µg of purified porcine TGFBIp was used as a
control. Lanes 2-6 have increasing amounts of crude human plasma.
The indicated volumes refer to the amount of crude plasma. Lane 7
is the molecular weight standard.
1000dust samples contain two predominant proteins with molecu-
lar weights of 60 kDa and about 65 kDa. However, the protein
bands were more intense in the lane with dissolved dust than
in the blank samples. The 60 kDa and 65 kDa proteins were
identified by MALDI-MS as human keratin-10 (Protein score:
119) and keratin-1 (Protein score: 93), respectively. Keratin-1
has a theoretical molecular weight of 66.1 kDa, while keratin-
10 has a theoretical molecular weight of 59.8 kDa.
Due to this observation, a new antiserum against human
TGFBIp (anti-TGFBIp134-236) was produced to detect and de-
termine the concentration of TGFBIp in plasma. An NH2-ter-
minal fragment constituting residues Gly111-Ile213 of the ma-
ture protein (equaling Gly134-Ile236 of the full-length protein)
was cloned and expressed in E. coli. The purification from the
insoluble fraction of the induced E. coli cells was performed
under denaturing conditions. The Ni2+-affinity chromatogra-
phy resulted in a highly pure elution of the His-tagged frag-
ment (Figure 3), which was used to immunize rabbits.
To detect TGFBIp in human plasma, increasing amounts
of normal crude plasma (1 nl-1 µl) were analyzed by
immunoblotting following reducing SDS-PAGE. Purified
TGFBIp from porcine corneas was used as a control (Figure
4). The anti-TGFBIp134-236 antiserum did not react with any
proteins in crude plasma but did react with purified porcine
TGFBIp. Thus, as expected from the high sequence identify
(98%) between the NH2-terminal fragments of human and
porcine TGFBIp [2], the TGFBIp antiserum recognized por-
cine TGFBIp.
Albumin (67 kDa) and IgG comprise 55% [37] and 10-
25% [38] of the total plasma protein mass, respectively. Thus,
depletion of albumin and IgG from plasma should remove 65-
80% of the total protein content allowing larger volumes of
plasma to be analyzed by SDS-PAGE. Consequently, this will
enhance the detection of TGFBIp if present in plasma. The
immunoblotting was repeated using increasing amounts of the
albumin/IgG-depleted plasma preparation equaling 1-20 µl of
crude plasma. Despite the high amounts of plasma loaded on
the gel, no reaction was observed (Figure 5).
The antiserum against the NH2-terminal fragment of hu-
man TGFBIp shows high specificity and its sensitivity was
determined using increasing amounts of purified porcine cor-
neal TGFBIp (Figure 6). In addition, increasing amounts of
the albumin/IgG-depleted human plasma was analyzed on the
same gel to verify the results depicted in Figure 5. The detec-
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Figure 5. Immunoblotting of albumin/IgG-depleted human plasma
using the specific anti-TGFBIp134-236 antiserum.  The immunoblot
shows increasing amounts of albumin/IgG-depleted human plasma
in 20 mM Tris-HCl (pH 7.4) and 100 mM NaCl. Each lane contains
20 µl of diluted albumin/IgG-depleted plasma. Lanes 1-5 contain
increasing amounts of albumin/IgG-depleted human plasma. The
indicated volumes refer to the equaling amount of crude plasma. Lane
6 contains 0.2 µg of purified porcine TGFBIp, which was used as a
control. Lane 7 is the molecular weight standard.
Figure 6. Detection limit of TGFBIp using purified porcine TGFBIp
from corneas.  The immunoblot shows increasing amounts of albu-
min/IgG-depleted human plasma and purified porcine TGFBIp (2-
500 ng). Lanes 1-3 show increasing amounts of albumin/IgG-depleted
human plasma. The indicated volumes refer to the equaling amount
of crude plasma. Lanes 4-11 show increasing amounts of purified
porcine TGFBIp. The amount of loaded porcine TGFBIp is indicated
for each lane. The detection limit is about 10 ng TGFBIp. Lane 12 is
the molecular weight standard.
1001tion limit of TGFBIp using the present immunoblotting method
was about 10 ng. Since no TGFBIp was detected in an albu-
min/IgG-depleted sample equaling 20 µl of crude plasma, the
present results show that the concentration of TGFBIp in
plasma is less than 0.5 mg/l. This estimation is based on the
assumption that the antiserum reacts equally with human and
porcine TGFBIp, which seems reasonable owing to the 98%
identity of the NH2-terminal fragments of TGFBIp.
DISCUSSION
 In an earlier study using immunoblotting and a polyclonal
antibody against a recombinant fragment of TGFBIp (Val210-
His683), our laboratory reported the presence of significant
amounts of TGFBIp in human plasma from both normal indi-
viduals and a patient suffering from granular corneal dystro-
phy [24]. However, the specificity of this antiserum, anti-p68βig-
h3, is now questioned as it reacts not only against TGFBIp but
also with an environmental protein contaminant that is present
even in blank samples only containing SDS sample buffer and
DTT. In this study, we have shown that the anti-p68βig-h3 anti-
serum is not specific for TGFBIp because it reacts strongly
with human keratin-1 under reducing conditions. Unfortu-
nately, keratin-1 migrates at the same position (about 65 kDa)
as TGFBIp under reducing conditions indicating that the pre-
vious interpretation of finding a significant amount of TGFBIp
in human plasma was in error [24]. Human keratins such as
keratin-10 (59.8 kDa), keratin-9 (62.1 kDa), epidermal kera-
tin-2 (65.9 kDa), and keratin-1 (66.1 kDa) are known to be
common laboratory contaminants and an analysis by use of
normal dust verified that human keratin-1 and -10 are indeed
abundant in dust. Therefore, the trace amount of the keratin-
10/1 pair in blank control samples probably originated from
dust. Keratins are intermediate filament proteins forming ap-
proximately 10 nm cytoskeletal filaments that stabilize the
structure of the cell. The keratin-10/1 pair is tissue-specific
and mainly expressed in suprabasal differentiating
keratinocytes within epidermis. Thus, keratin-1 and keratin-
10 together with epidermal keratin-2 are characteristic of the
post-mitotic upper layer of epidermis and therefore likely to
end up in dust as the cornified and dead keratinocytes desqua-
mate from the skin [39]. Since keratin-1 and the recombinant
TGFBIp-fragment (Val210-His683 of TGFBIp) show no signifi-
cant sequence similarity, it is very unlikely that antibodies will
recognize both proteins through reactivity with shared epitopes.
However, contamination of an antigen preparation with small
amounts of dust prior to immunizations could lead to reactiv-
ity of the antiserum against keratin-1 in addition to TGFBIp.
Since both mature TGFBIp [2] and keratin-1 migrate with
molecular masses of about 65 kDa in reducing SDS-PAGE,
reactivity against contaminating keratin-1 in immunoblotting
is easily misinterpreted as detection of TGFBIp. The fact that
we observe reactivity of the anti-p68βig-h3 antiserum against
keratin-1 only under reducing conditions is probably because
all keratins of the cornified layer of epidermis are cross-linked
by intermolecular disulfide bonds forming high molecular
weight structures [40], which prevent the protein from enter-
ing the gel under non-reducing conditions. Thus, we conclude
that the previous strong detection of TGFBIp in plasma by
immunoblotting [24] was incorrect, demonstrating the impor-
tance of using direct protein identification methods such as
mass spectrometry or NH2-terminal sequencing. Because of
this we have produced a new antiserum against TGFBIp and
reinvestigated the presence of TGFBIp in normal human
plasma with the aim of determining its concentration. With
this anti-TGFBIp134-236 antiserum, which showed no indica-
tions of reactivity with other proteins, we could not detect
TGFBIp in normal crude plasma or in plasma depleted of al-
bumin and IgG under the conditions tested. Based on the de-
tection limit, which was estimated using purified TGFBIp from
porcine corneas, we conclude that the concentration of TGFBIp
in plasma is below 0.5 mg/l, which is in the range of so-called
tissue leakage proteins caused, for example, by tissue turn-
over and thus with no physiological function in plasma [37].
Thus, our observation is consistent with another study report-
ing the detection of TGFBIp in the µg/ml range in serum from
healthy individuals and patients with colorectal cancer using
an ELISA assay [41].
The present evidence against a plasma derived origin for
corneal TGFBIp has implications for the pathogenesis of in-
herited corneal disorders caused by mutations in the TGFBI
gene. It suggests that corneal TGFBIp deposits in individuals
with mutations in the TGFBI gene originate from local syn-
thesis in the cornea rather than from the plasma as in
hypergammaglobulinemia.
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